WPIL's stock has halved as its domestic business stumbled, but strong international operations have cushioned the blow. With a record order book and a valuation of just 2.7 times book value, can fresh project wins and improved cash generation drive the next leg of growth?
EBITDA tripled, PAT jumped 2.7x, and Honasa declared its first dividend. But margins expanded because advertising costs fell, not because the business became structurally more profitable. At 66x earnings, is the turnaround real, or has the market already priced it in?
The business transformed first. The stock followed later. After years of being overlooked, VA Tech Wabag has been re-rated sharply. The question now is whether its growth, cash generation and order pipeline justify 27x earnings.
Over the last few years, Supriya Life Sciences has expanded beyond its traditional API business. By targeting markets dominated by Chinese suppliers and investing in formulations, contrast media APIs, peptides, and CDMO services, the company is increasing its presence across the pharmaceutical value chain. The key question is whether these initiatives can transform it into a diversified pharmaceutical player.
A small-cap API intermediate manufacturer is attempting a transformation into a global pharmaceutical platform through Rs 3,000 crore of acquisitions, including Sanofi's anti-TB brands and Japan's MicroBiopharm. The opportunity is compelling, but can the balance sheet support the ambition?
A 2W-metal company is quietly buying its way into aerospace and satellite supply chains. It saw its FY26 profit after tax jump 41%, reduced its net debt to near zero, and watched its stock double. At ~40x, is the aerospace bet already in the price?
Alkyl Amines Chemicals manufactures critical reagents used in peptide synthesis and pharmaceutical chemistry. With global leadership in several amine molecules and exposure to the GLP-1 ecosystem, the company is emerging as a key beneficiary of India’s pharmaceutical manufacturing scale-up. The question now is whether execution can keep pace with the scale of the opportunity.
Manorama Industries’ FY26 revenue grew 76%, ROE touched 40%, and EBITDA margin expanded to 27%. The stock now trades at 34x earnings. But after two years of negative operating cash flow before a sharp rebound in FY26, the key question is whether margins, capacity expansion, pricing power, and cash conversion can continue to hold together.
Acutaas Chemicals was once viewed primarily as a pharmaceutical intermediates manufacturer. Today, the company is building a broader specialty chemicals platform spanning CDMO, battery electrolyte additives, semiconductor chemicals, and fine chemistry. As multiple growth engines begin scaling simultaneously, the key question is whether execution can justify the sharp valuation re-rating already underway.
A Rs 21,200 crore order book, the commercial rollout of Pinaka rockets, and rapidly scaling international defence orders are transforming Solar Industries from an industrial explosives maker into one of India’s fastest-growing defence manufacturers. Investors are now watching whether this momentum can sustain the company’s next phase of compounding.
Yatra Online Ltd continues to grow bookings, revenue, and profitability, yet the stock has corrected sharply from its highs. With corporate travel, higher-margin segments, and platform expansion now driving strategy, the market is no longer asking whether Yatra can grow, but whether it can deliver consistent, predictable earnings over time.
For years, MTAR Technologies operated under the radar, building components across nuclear, clean energy, and defence. Now, as global demand converges across these sectors, its order book is surging and capacity is stretched. With deep technical moats and multiple growth engines firing at once, the question now is: are the valuations stretched?
In Q3 FY26, CP Plus's revenue grew 37% year-on-year, while adjusted PAT surged 139% and EBITDA margins expanded from 8.3% in FY25 to 12.7%. In a weak broader market, such momentum raises two questions: what is driving this transformation, and do current valuations still hold up?
ITC Limited shares have underperformed both cigarette peers and the broader FMCG pack, as the excise duty hike intensifies concerns over a potential shift toward illicit trade. Long-term investors should closely monitor FY27 earnings, when the full impact of the tax changes is likely to become evident.
In the last quarter, Campus Activewear reported revenue of Rs 588 crore, EBITDA of Rs 115.8 crore, and PAT of Rs 63.7 crore. The bigger question, however, is whether this marks the beginning of a sustained shift toward a more premium, higher-margin business, or simply a strong phase in a cyclical consumer category.
Despite 30%+ margins and exposure to the GLP-1 opportunity, Natco Pharma continues to trade at a modest valuation. Is the 10x P/E a structural constraint or a mispriced opportunity?
NMDC just delivered its best year ever, crossing 50 million tonnes of iron ore production. But falling prices, rising costs, and Rs 10,000+ crore stuck in receivables are keeping profits, and the stock, under pressure.
A company that was loss-making in FY22 now trades at 85x earnings. The question for investors is whether GE Vernova’s margin expansion and order pipeline justify the premium, or if expectations have run ahead of reality.
A decade after it began as a robotics lab experiment at IIT Madras, Ather Energy has emerged as one of India’s leading electric two-wheeler makers, with an 18% market share. Revenues are rising, margins are expanding, and losses are narrowing. But with the stock trading at a 9x P/S and competition intensifying, the key question is whether this momentum reflects a durable structural shift or a favourable cycle.
HDFC Bank is facing a convergence of global and domestic shocks that has unsettled investor sentiment. As the bank pivots from growth to stability amid leadership uncertainty, a key question emerges: is the market overreacting?
Even as global sentiment turns against coal, NTPC is doubling down on thermal capacity while expanding into renewables, nuclear, and storage, and relying on a regulated framework that ensures stable returns. The question now is whether NTPC can accelerate earnings growth beyond its steady compounding base.
Finolex Cables is delivering robust growth and sits on one of the strongest balance sheets in the sector. Yet, the stock has remained flat for years. Trading at a steep discount to peers, the company faces structural margin pressure in its core business, an underperforming fibre segment, and a promoter dispute. The key question is whether these are temporary headwinds or deeper structural constraints.
Rs 1,400 crore in capex. Five simultaneous bets. One core strength in fluorine chemistry. The transformation is underway, but can Navin Fluorine deliver?
India’s first global telecom OEM crossed the billion-dollar revenue mark in FY25, but FY26 has brought a sharp slowdown. With Rs 2,363 crore in inventory and a delayed BSNL order, can Tejas Networks pivot to international private telcos?
Ram Charan’s Peddi defies the odds to blast past Rs 400 crore globally in just 14 days
Entertainment39 min ago
Ram Charan's sports drama Peddi, directed by Buchi Babu Sana, has become a massive success, earning over Rs 400 crore worldwide in just 14 days. It has broken records for the actor, becoming his highest grossing solo film and the second to cross Rs 200 crore domestically. Despite controversy, Peddi has been a significant milestone in Ram Charan's career.
